Long-Time Novo Investor Cuts Stake Citing Weight-Loss Drug Hype
- GAM Investments’ flagship fund beats 88% of peers this year
- Fund manager cuts Novo exposure in half in recent months
This article is for subscribers only.
A top-performing European fund manager is calling time on “hype” around weight-loss drugs that has sent Novo Nordisk A/S’s stock price rallying more than 50% this year.
Niall Gallagher, who runs an equity fund for GAM Investments that has returned 14% this year, said he had reduced a position in the Danish drugmaker by about half in the past few months, partly to reflect the surge in stock valuations as sales of its appetite-suppressing medications — known as GLP-1s — skyrocketed.